New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.

Article  PubMed  PubMed Central  Google Scholar 

Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34:927–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst. 2022;114:391–9.

Article  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

Article  PubMed  Google Scholar 

Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast. 2021;57:5–17.

Article  PubMed  PubMed Central  Google Scholar 

Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195.

Article  PubMed  PubMed Central  Google Scholar 

Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383:2557–70.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

Article  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61.

Article  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.

Article  CAS  PubMed  Google Scholar 

Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15.

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942–50.

Article  CAS  PubMed  Google Scholar 

Goetz MP, Toi M, Huober J, Sohn J, Tredan O, Park IH, et al. LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol. 2022;33:S1384.

Article  Google Scholar 

Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 2022;24:17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987–98. This paper reports the preplanned efficacy interim analysis of the monarchE trial of 2 years of abemaciclib added to adjuvant ET for high-risk node-positive HR+/HER2− EBC in which the primary endpoint of iDFS was met at 19 months of follow-up.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32:1571–81. This is an updated analysis of the monarchE trial showing that iDFS improvement with 2 years of abemaciclib added to adjuvant ET for high-risk node-positive HR+/HER2− EBC persists at 27 months of follow-up, leading to FDA approval of abemaciclib use in this setting. This analysis also found that Ki-67 index was prognostic but not predictive of abemaciclib benefit in this population.

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77–90.

Article  CAS  PubMed  Google Scholar 

Martin M, Hegg R, Kim S-B, Schenker M, Grecea D, Garcia-Saenz JA, et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol. 2022;8:1190–4.

Article  PubMed  PubMed Central  Google Scholar 

Rugo HS, O’Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616–27.

Article  CAS  PubMed  Google Scholar 

Tarantino P, Jin Q, Mittendorf EA, King TA, Curigliano G, Tolaney SM. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. Ann Oncol. 2022;33:845–7.

Article  CAS  PubMed  Google Scholar 

• Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22:212–22. This paper reports the second interim analysis of the PALLAS trial of 2 years of palbociclib added to adjuvant ET for mixed-risk HR+/HER2− EBC, showing no benefit for iDFS at 24 months of follow-up. At this point, the futility boundary was crossed, and palbociclib was discontinued in patients still receiving it on the trial.

Article  CAS  PubMed  Google Scholar 

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40:282–93.

Article  CAS  PubMed  Google Scholar 

• Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S-B, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial. J Clin Oncol. 2021;39:1518–30. This paper reports the PENELOPE-B trial of 1 year of palbociclib added to adjuvant ET for high-risk HR+/HER2− EBC (with residual disease after neoadjuvant chemotherapy), showing no benefit for iDFS at 42.8 months of follow-up. This report also highlights the importance of longer-term follow-up as PENELOPE-B saw transient iDFS curve separation at 6 months that dissipated after a few more years of follow-up.

Article  CAS  PubMed  Google Scholar 

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395:817–27.

Article  CAS  PubMed  Google Scholar 

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, et al. Treatment exposure and discontinuation in the palbociclib collaborative adjuvant study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022;40:449–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wander SA, O’Brien N, Litchfield LM, O’Dea D, Morato Guimaraes C, Slamon DJ, et al. Targeting CDK4 and 6 in cancer therapy: emerging preclinical insights related to abemaciclib. Oncologist. 2022;27:811–21.

Article  PubMed  PubMed Central  Google Scholar 

Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26:1067-1080.e8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, et al. Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3β and activates WNT signaling. Mol Cancer Res. 2018;16:333–44.

Article  CAS  PubMed  Google Scholar 

Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw. 2021;1–8.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23:4055–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.

Article  CAS  PubMed  Google Scholar 

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.

Article 

留言 (0)

沒有登入
gif